Part of the role of the IOS is to keep everyone informed around new developments in the prevention and treatment of Osteoporosis.
The Committee for Medicinal Products for Human Use (CHMP), has now agreed to grant marketing authorisation for Romosozumab in the treatment of severe postmenopausal osteoporosis. This agreement came following a re-examination procedure. This means this medication will shortly be available to patients in Europe, including Ireland, following its introduction to numerous countries globally. Its availability in Ireland could take up to one year.